following a resubmission:
pomalidomide (Imnovid®) is accepted for use within NHS Scotland.
Indication under review: in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Pomalidomide plus dexamethasone significantly increased progression-free survival compared with high-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of pomalidomide. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice186KB (PDF)
Medicine details
- Medicine name:
- pomalidomide (Imnovid)
- SMC ID:
- 972/14
- Indication:
- in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 08 December 2014